Sefaxersen Phase III IgAN Interim Success
Analysis based on 6 articles · First reported Sep 23, 2026 · Last updated Sep 24, 2026
Positive Phase III interim data for sefaxersen strengthens the commercial outlook for Roche and Ionis in the IgAN market, potentially supporting upside in their shares and reinforcing the value of their licensing partnership. The readout raises competitive pressure on other IgAN drug developers and could shift investor expectations toward targeted complement-pathway therapies.
F. Hoffmann-La Roche — Genentech, a member of the Roche Group, and its partner Ionis Pharmaceuticals announced positive prespecified interim results from the ongoing Phase III IMAgINATION study evaluating investigational sefaxersen in adults with primary IgA nephropathy (IgAN). The study met its primary endpoint, with sefaxersen achieving statistically significant and clinically meaningful improvements in proteinuria reduction compared to placebo at 37 weeks, as measured by 24-hour urine protein-to-creatinine ratio (UPCR). Sefaxersen is a once-monthly subcutaneous injection designed for self-administration and is the first mRNA-targeted therapy for IgAN, inhibiting complement factor B production in the liver. The safety and tolerability profile was consistent with previously reported data, with no new safety signals identified. Levi Garraway, F. Hoffmann-La Roche — Genentech chief medical officer, said the results show the clinical potential of sefaxersen to modify a key surrogate endpoint of kidney function and may offer a new treatment option to slow disease progression and reduce the long-term need for dialysis or kidney transplantation. Bonnie Schneider of the IgA Nephropathy Foundation noted the positive results represent the potential of targeted, convenient treatments. The IMAgINATION study will continue as a blinded study evaluating kidney function over two years via eGFR at week 105. F. Hoffmann-La Roche — Genentech plans to present interim data at an upcoming medical congress and share with health authorities to bring the treatment to patients as soon as possible. Roche licensed sefaxersen from Ionis for complement mediated diseases.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard